Maraviroc as Graft Versus Host Disease Prophylaxis in Pediatric and Adult Stem Cell Transplant Recipients

Trial Profile

Maraviroc as Graft Versus Host Disease Prophylaxis in Pediatric and Adult Stem Cell Transplant Recipients

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Maraviroc (Primary)
  • Indications Graft-versus-host disease
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 25 Jun 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 15 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top